Protocol for a multi-centered, stepped wedge, cluster randomized controlled trial of the de-adoption of oral chlorhexidine prophylaxis and implementation of an oral care bundle for mechanically ventilated critically ill patients: the CHORAL study
Background Routine application of chlorhexidine oral rinse is recommended to reduce risk of ventilator-associated pneumonia (VAP) in mechanically ventilated patients. Recent reappraisal of the evidence from two meta-analyses suggests chlorhexidine may cause excess mortality in non-cardiac surgery patients and does not reduce VAP. Mechanisms for possible excess mortality are unclear. The CHORAL study will evaluate the impact of de-adopting chlorhexidine and implementing an oral care bundle (excluding chlorhexidine) on mortality, infection-related ventilator-associated complications (IVACs), and oral health status. Methods The CHORAL study is a stepped wedge, cluster randomized controlled trial in six academic intensive care units (ICUs) in Toronto, Canada. Clusters (ICU) will be randomly allocated to six sequential steps over a 14-month period to de-adopt oral chlorhexidine and implement a standardized oral care bundle (oral assessment, tooth brushing, moisturization, and secretion removal). On study commencement, all clusters begin with a control period in which the standard of care is oral chlorhexidine. Clusters then begin crossover from control to intervention every 2 months according to the randomization schedule. Participants include all mechanically ventilated adults eligible to receive the standardized oral care bundle. The primary outcome is ICU mortality; secondary outcomes are IVACs and oral health status. We will determine demographics, antibiotic usage, mortality, and IVAC rates from a validated local ICU clinical registry. With six clusters and 50 ventilated patients on average each month per cluster, we estimate that 4200 patients provide 80% power after accounting for intracluster correlation to detect an absolute reduction in mortality of 5.5%. We will analyze our primary outcome of mortality using a generalized linear mixed model adjusting for time to account for secular trends. We will conduct a process evaluation to determine intervention fidelity and to inform interpretation of the trial results. Discussion The CHORAL study will inform understanding of the effectiveness of de-adoption of oral chlorhexidine and implementation of a standardized oral care bundle for decreasing ICU mortality and IVAC rates while improving oral health status. Our process evaluation will inform clinicians and decision makers about intervention delivery to support future de-adoption if justified by trial results. Trial registration ClinicalTrials.gov, NCT03382730. Registered on December 26, 2017..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Trials - 20(2019), 1 vom: 24. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dale, Craig M. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Chlorhexidine |
|---|
| Anmerkungen: |
© The Author(s). 2019 |
|---|
| doi: |
10.1186/s13063-019-3673-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR030114152 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR030114152 | ||
| 003 | DE-627 | ||
| 005 | 20230519161908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-019-3673-0 |2 doi | |
| 035 | |a (DE-627)SPR030114152 | ||
| 035 | |a (SPR)s13063-019-3673-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dale, Craig M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protocol for a multi-centered, stepped wedge, cluster randomized controlled trial of the de-adoption of oral chlorhexidine prophylaxis and implementation of an oral care bundle for mechanically ventilated critically ill patients: the CHORAL study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2019 | ||
| 520 | |a Background Routine application of chlorhexidine oral rinse is recommended to reduce risk of ventilator-associated pneumonia (VAP) in mechanically ventilated patients. Recent reappraisal of the evidence from two meta-analyses suggests chlorhexidine may cause excess mortality in non-cardiac surgery patients and does not reduce VAP. Mechanisms for possible excess mortality are unclear. The CHORAL study will evaluate the impact of de-adopting chlorhexidine and implementing an oral care bundle (excluding chlorhexidine) on mortality, infection-related ventilator-associated complications (IVACs), and oral health status. Methods The CHORAL study is a stepped wedge, cluster randomized controlled trial in six academic intensive care units (ICUs) in Toronto, Canada. Clusters (ICU) will be randomly allocated to six sequential steps over a 14-month period to de-adopt oral chlorhexidine and implement a standardized oral care bundle (oral assessment, tooth brushing, moisturization, and secretion removal). On study commencement, all clusters begin with a control period in which the standard of care is oral chlorhexidine. Clusters then begin crossover from control to intervention every 2 months according to the randomization schedule. Participants include all mechanically ventilated adults eligible to receive the standardized oral care bundle. The primary outcome is ICU mortality; secondary outcomes are IVACs and oral health status. We will determine demographics, antibiotic usage, mortality, and IVAC rates from a validated local ICU clinical registry. With six clusters and 50 ventilated patients on average each month per cluster, we estimate that 4200 patients provide 80% power after accounting for intracluster correlation to detect an absolute reduction in mortality of 5.5%. We will analyze our primary outcome of mortality using a generalized linear mixed model adjusting for time to account for secular trends. We will conduct a process evaluation to determine intervention fidelity and to inform interpretation of the trial results. Discussion The CHORAL study will inform understanding of the effectiveness of de-adoption of oral chlorhexidine and implementation of a standardized oral care bundle for decreasing ICU mortality and IVAC rates while improving oral health status. Our process evaluation will inform clinicians and decision makers about intervention delivery to support future de-adoption if justified by trial results. Trial registration ClinicalTrials.gov, NCT03382730. Registered on December 26, 2017. | ||
| 650 | 4 | |a Chlorhexidine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Critical care |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ventilator-associated pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oral care |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Stepped-wedge cluster randomized controlled trial |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Process evaluation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mechanical ventilation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Rose, Louise |4 aut | |
| 700 | 1 | |a Carbone, Sarah |4 aut | |
| 700 | 1 | |a Smith, Orla M. |4 aut | |
| 700 | 1 | |a Burry, Lisa |4 aut | |
| 700 | 1 | |a Fan, Eddy |4 aut | |
| 700 | 1 | |a Amaral, Andre Carlos Kajdacsy-Balla |4 aut | |
| 700 | 1 | |a McCredie, Victoria A. |4 aut | |
| 700 | 1 | |a Pinto, Ruxandra |4 aut | |
| 700 | 1 | |a Quiñonez, Carlos R. |4 aut | |
| 700 | 1 | |a Sutherland, Susan |4 aut | |
| 700 | 1 | |a Scales, Damon C. |4 aut | |
| 700 | 1 | |a Cuthbertson, Brian H. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d London : BioMed Central, 2000 |g 20(2019), 1 vom: 24. Okt. |w (DE-627)SPR03004751X |w (DE-600)2040523-6 |x 1745-6215 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2019 |g number:1 |g day:24 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13063-019-3673-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2019 |e 1 |b 24 |c 10 | ||